Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-masked Study of DE-111 Ophthalmic Solution Versus Timolol Ophthalmic Solution 0.5% in Patients With Primary Open Angle Glaucoma or Ocular Hypertension - Phase 3, Confirmatory Study -

NCT01342094 is registered in ClinicalTrials.gov with Santen Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT01342094
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01342094 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-masked Study of DE-111 Ophthalmic Solution Versus Timolol Ophthalmic Solution 0.5% in Patients With Primary Open Angle Glaucoma or Ocular Hypertension - Phase 3, Confirmatory Study -
Lead sponsor
Santen Pharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2011
Completion date
Not reported
Enrollment
166 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ocular hypertension, open angle glaucoma